Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-derived inhibitory immunoglobulin G4kappa antibody (BO2C11) produced by an immortalized memory B-lymphocyte cell line interferes with the binding of factor VIII to phospholipid surfaces and to von Willebrand factor. The structure of a Fab fragment derived from this antibody complexed with the factor VIII C2 domain was determined at 2.0 A resolution. The Fab interacts with solvent-exposed basic and hydrophobic side chains that form a membrane-association surface of factor VIII. This atomic resolution structure suggests a variety of amino acid substitutions in the C2 domain of factor VIII that might prevent the binding of anti-C2 inhibitor antibodies without significantly compromising the procoagulant functions of factor VIII.

[1]  E. Saenko,et al.  A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor (*) , 1995, The Journal of Biological Chemistry.

[2]  M. Shima,et al.  A Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Factor VIII Binding to von Willebrand Factor and to Phosphatidylserine , 1993, Thrombosis and Haemostasis.

[3]  M. Shima,et al.  Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients. , 1999, Journal of immunological methods.

[4]  M. Shima,et al.  Some human inhibitor antibodies interfere with factor VIII binding to factor IX. , 1998, Blood.

[5]  R. Biggs,et al.  The Treatment of Patients who have Factor‐VIII Antibodies , 1973, British journal of haematology.

[6]  J. Vermylen,et al.  A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. , 2000, Blood.

[7]  R. Biggs,et al.  The Mode of Action of Antibodies which Destroy Factor VIII , 1972, British journal of haematology.

[8]  W. Kane,et al.  Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. , 1988, Blood.

[9]  S. Shapiro,et al.  The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. , 1988, Blood.

[10]  E. Getzoff,et al.  Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains. , 1998, Blood cells, molecules & diseases.

[11]  R. Huber,et al.  Crystal structures of the membrane-binding C2 domain of human coagulation factor V , 1999, Nature.

[12]  J. Berzofsky.  Intrinsic and extrinsic factors in protein antigenic structure. , 1985, Science.

[13]  B. Keyt,et al.  Structure of human factor VIII , 1984, Nature.

[14]  R. Bagnall,et al.  Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A , 1998, Thrombosis and Haemostasis.

[15]  J. Healey,et al.  Antigenicity of putative phospholipid membrane-binding residues in factor VIII. , 2001, Blood.

[16]  K. Fujikawa,et al.  Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. , 2000, Blood.

[17]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[18]  I. Mikhailenko,et al.  Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism* , 1999, The Journal of Biological Chemistry.

[19]  G. E. Gilbert,et al.  Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. , 1995, Blood.

[20]  P. Fay.  Regulation of Factor VIIIa in the Intrinsic Factor Xase , 1999, Thrombosis and Haemostasis.

[21]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[22]  D. Moras,et al.  Correlation between segmental mobility and the location of antigenic determinants in proteins , 1984, Nature.

[23]  P. Lenting,et al.  The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.

[24]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[25]  J. Healey,et al.  Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. , 1998, Blood.

[26]  G. Knutson,et al.  Molecular cloning of a cDNA encoding human antihaemophilic factor , 1984, Nature.

[27]  L. Hoyer,et al.  Inactivation of factor VIII coagulant activity by two different types of human antibodies. , 1982, Blood.

[28]  J. Vermylen,et al.  Some Factor VIII (FVIII) Inhibitors Recognise a FVIII Epitope(s) that Is Present only on FVIII-vWF Complexes , 1999, Thrombosis and Haemostasis.

[29]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[30]  M F Hoylaerts,et al.  Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. , 1998, Blood.

[31]  K. Fujikawa,et al.  Structure of the C2 domain of human factor VIII at 1.5 Å resolution , 1999, Nature.

[32]  J. Oldenburg,et al.  Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation , 1995, Thrombosis and Haemostasis.

[33]  I. Sussman,et al.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. , 1977, The Journal of clinical investigation.

[34]  C R Kissinger,et al.  Rapid automated molecular replacement by evolutionary search. , 1999, Acta crystallographica. Section D, Biological crystallography.

[35]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[36]  P. Lollar,et al.  Activation of porcine factor VIII:C by thrombin and factor Xa. , 1985, Biochemistry.

[37]  J. Pouchot,et al.  Acquired hemophilia due to factor VIII inhibitors in 34 patients. , 1998, The American journal of medicine.

[38]  J. Vermylen,et al.  Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. , 1999, Blood.

[39]  F E Preston,et al.  Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. , 1995, Blood.

[40]  H. Brackmann,et al.  Inhibitors in German Hemophilia A Patients Treated with a Double Virus Inactivated Factor VIII Concentrate Bind to the C2 Domain of FVIII Light Chain , 1999, Thrombosis and Haemostasis.

[41]  B. Binder,et al.  Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. , 2000, Blood.

[42]  J. Sixma,et al.  Kinetics of factor VIII-von Willebrand factor association. , 1996, Blood.

[43]  G. E. Gilbert,et al.  Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. , 1993, Biochemistry.

[44]  L. Hoyer,et al.  Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. , 1994, Seminars in hematology.

[45]  E G Tuddenham,et al.  Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. , 1994, Nucleic acids research.

[46]  R. Biggs.  Human blood coagulation, haemostasis and thrombosis; , 1972 .

[47]  K. Nogami,et al.  Identification of a factor VIII peptide, residues 2315–2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect , 1999, British journal of haematology.

[48]  Philipp Bucher,et al.  The discoidin domain family revisited: New members from prokaryotes and a homology‐based fold prediction , 1998, Protein science : a publication of the Protein Society.

[49]  J. Arnout,et al.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993, Blood.

[50]  J. Healey,et al.  Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. , 2000, Blood.